Manuel Dómine

32.9k total citations · 1 hit paper
123 papers, 3.0k citations indexed

About

Manuel Dómine is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Manuel Dómine has authored 123 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Oncology, 73 papers in Pulmonary and Respiratory Medicine and 30 papers in Molecular Biology. Recurrent topics in Manuel Dómine's work include Lung Cancer Treatments and Mutations (67 papers), Lung Cancer Research Studies (43 papers) and Lung Cancer Diagnosis and Treatment (34 papers). Manuel Dómine is often cited by papers focused on Lung Cancer Treatments and Mutations (67 papers), Lung Cancer Research Studies (43 papers) and Lung Cancer Diagnosis and Treatment (34 papers). Manuel Dómine collaborates with scholars based in Spain, United States and Germany. Manuel Dómine's co-authors include Rafael Rosell, Carlos Camps, Miquel Tarón, José Javier Sánchez, José Miguel Sánchez, Vicente Alberola, David R. Gandara, Kathleen D. Danenberg, Dolores Isla and Manuel Cobo and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Manuel Dómine

119 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

2002 551 citations Carlos Camps, Manuel Dómine et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manuel Dómine Spain	24	1.9k	1.4k	1.2k	538	492	123	3.0k
Joo Hang Kim South Korea	27	1.9k 1.0×	1.9k 1.3×	789 0.7×	426 0.8×	209 0.4×	91	3.0k
Vera Gorbounova Russia	13	2.2k 1.2×	1.8k 1.3×	617 0.5×	354 0.7×	407 0.8×	23	3.2k
Francisco Robert United States	28	1.8k 0.9×	1.4k 1.0×	1.1k 1.0×	312 0.6×	338 0.7×	107	3.2k
H. Au Canada	13	2.9k 1.5×	1.1k 0.7×	681 0.6×	979 1.8×	597 1.2×	23	3.5k
Hiroshige Yoshioka Japan	37	3.2k 1.7×	3.6k 2.5×	940 0.8×	589 1.1×	499 1.0×	204	4.5k
Saiama N. Waqar United States	29	1.7k 0.9×	1.9k 1.3×	654 0.6×	551 1.0×	310 0.6×	143	2.9k
S. Kakolyris Greece	32	1.9k 1.0×	925 0.6×	1.0k 0.9×	816 1.5×	286 0.6×	90	3.0k
Kiyotaka Yoh Japan	35	3.0k 1.6×	2.6k 1.8×	1.4k 1.2×	740 1.4×	562 1.1×	271	4.6k
Ticiana Leal United States	24	2.5k 1.3×	1.5k 1.1×	780 0.7×	435 0.8×	592 1.2×	98	3.3k
Russell F. DeVore United States	17	2.8k 1.5×	2.4k 1.7×	1.3k 1.1×	460 0.9×	374 0.8×	29	3.8k

Countries citing papers authored by Manuel Dómine

Since Specialization

Citations

This map shows the geographic impact of Manuel Dómine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Dómine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Dómine more than expected).

Fields of papers citing papers by Manuel Dómine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Dómine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Dómine. The network helps show where Manuel Dómine may publish in the future.

Co-authorship network of co-authors of Manuel Dómine

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Dómine. A scholar is included among the top collaborators of Manuel Dómine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Dómine. Manuel Dómine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nadal, Ernest, Paloma Martín-Martorell, José Carlos Benítez, et al.. (2025). Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma. Lung Cancer. 203. 108545–108545.

John, Thomas, Christian Grohé, Jonathan W. Goldman, et al.. (2024). Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8005–8005. 15 indexed citations

Levy, Benjamin, Luis Paz‐Ares, Wu‐Chou Su, et al.. (2024). Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02.. Journal of Clinical Oncology. 42(16_suppl). 8617–8617. 5 indexed citations

Postel‐Vinay, Sophie, Matthieu Texier, Mihaela Aldea, et al.. (2023). Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. British Journal of Cancer. 130(3). 417–424. 4 indexed citations

Calvo, Virginia, Carlos Camps, Enric Carcereny, et al.. (2023). Difficulties on the access to innovative targeted therapies for lung cancer in Spain. Clinical & Translational Oncology. 26(3). 597–612. 3 indexed citations

Puerto‐Nevado, Laura del, et al.. (2022). Galectin-1, a novel promising target for outcome prediction and treatment in SCLC. Biomedicine & Pharmacotherapy. 156. 113987–113987. 6 indexed citations

Dómine, Manuel, Teresa Morán, Dolores Isla, et al.. (2020). SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). Clinical & Translational Oncology. 22(2). 245–255. 40 indexed citations

Tsuboi, Masahiro, Yi‐Long Wu, Jian He, et al.. (2020). 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence. Annals of Oncology. 31. S1378–S1378. 3 indexed citations

Morgensztern, Daniel, Nina Karaseva, Enriqueta Felip, et al.. (2019). An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Lung Cancer. 136. 74–79. 19 indexed citations

10.

Provencio, Mariano, Enric Carcereny, Delvys Rodríguez‐Abreu, et al.. (2019). Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Translational Lung Cancer Research. 8(4). 461–475. 43 indexed citations

11.

Rodríguez‐Abreu, Delvys, M.C. Garassino, Emilio Esteban, et al.. (2018). KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. Annals of Oncology. 29. ix164–ix164. 4 indexed citations

12.

Garassino, Marina Chiara, Delvys Rodríguez‐Abreu, S. Gadgeel, et al.. (2018). PD.1.01 Health-Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189. Journal of Thoracic Oncology. 13(9). S155–S155. 1 indexed citations

13.

Arce‐Lara, Carlos, Edurne Arriola, Paal Brunsvig, et al.. (2018). P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S741–S741. 1 indexed citations

14.

Aguado, Carlos, Manuel Dómine, Antonio Calles, et al.. (2018). 159P Clinical activity of afatinib in a cohort of patients with lung adenocarcinoma harbouring uncommon EGFR mutations: A Spanish retrospective multicentre study. Journal of Thoracic Oncology. 13(4). S95–S96. 1 indexed citations

15.

González-Larriba, J.L., Martín Lázaro-Quintela, Manuel Cobo, et al.. (2017). Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis. Translational Lung Cancer Research. 6(S1). S21–S34. 11 indexed citations

16.

Cañadas, Israel, Federico Rojo, Álvaro Taus, et al.. (2013). Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer. Clinical Cancer Research. 20(4). 938–950. 107 indexed citations

17.

Garrido, Pilar, Rafael Rosell, F. Andreu, et al.. (2013). Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study. Lung Cancer. 81(1). 84–90. 19 indexed citations

18.

Izarzugaza, Yann, Manuel Dómine, Federico Rojo, et al.. (2012). Prevalence of EGFR mutations in non-small cell lung cancer (NSCLC) smoker patients.. Journal of Clinical Oncology. 30(15_suppl). e21015–e21015. 1 indexed citations

19.

Contreras, Jorge, Francisco Valcárcel, Manuel Dómine, & Yolanda Escobar. (2008). Sensitivity to change of the Spanish validated Memorial Pain Assessment Card in cancer patients. Clinical & Translational Oncology. 10(10). 654–659. 3 indexed citations

20.

Virizuela, Juan Antonio, Jesús Florián, M. Lomas, et al.. (2003). Gemcitabine/Vinorelbine in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines: Results of a Phase II Trial. Clinical Breast Cancer. 4(1). 46–50. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact